Patent SG-11201809858R-A (SG)
Title: Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
Inventor: FISCHKOFF STEVEN
IPC: C12N5/0783
Filed: 2017-05-05
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\"\" WO 2017/196657 Al 16 November 2017 (16.11.2017) WIPO I PCT (51) International Patent Classification: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, A61K 35/17 (2015.01) Cl 2N 5/0783 (2010.01) HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, A61P 35/00 (2006.01) KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, (21) International Application Number: MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PCT/US2017/031255 PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (22) International Filing Date: TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 05 May 2017 (05.05.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (30) Priority Data: TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 62/333,187 07 May 2016 (07.05.2016) US EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 62/333,186 07 May 2016 (07.05.2016) US MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 62/415,918 01 November 2016 (01.11.2016) US TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 62/415,954 01 November 2016 (01.11.2016) US KM, ML, MR, NE, SN, TD, TG). (71) Applicant: ANTHROGENESIS CORPORATION Published: [US/US]; 7 Powder Horn Drive, Warren, NJ 07059 (US). — with international search report (Art. 21(3)) (72) Inventors; and (71) Applicants: FISCHKOFF, Steven, Alan [US/US]; 5 Canoe Brook Road, Short Hills, NJ 07078 (US). HERZBERG, Uri [US/US]; 148 Maple Street, Bridge- water, NJ 08807 (US). KANG, Lin [CN/US]; 1106 Tim- ber Oaks Road, Edison, NJ 08820 (US). MURPHY, Bri- an [US/US]; 99 1/2 Greene Street, Apt. 1, Jersey City, NJ 070302 (US). NORDBERG, Andrea [US/US]; 162 Steuben Street, Apt. 3, Jersey City, NJ 07302 (US). VOSKINARIAN-BERSE, Vanessa [US/US]; 1670 Val- ley Road, Millington, NJ 07946 (US). WILSON, Keith [US/US]; 224 Old Tote Road, Mountainside, NJ 07092 (US). ZHANG, Xiaokui [US/US]; 68 Blazier Road, Mar- tinsville, NJ 08836 (US). MYINT, Han [US/US]; Edge- mere Road, Livingston, NJ 07039 (US). HUSSEIN, Mo- hamed [US/US]; 16107 Copeland Farms Road, Odessa, FL 33556 (US). Agent: GEORGE, Nikolaos, C. et al.; Jones Day, 250 (74) Vesey Street, New York, NY 10281-1047 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (81) ,_ 1 (54) Title: METHODS OF TREATING ACUTE MYELOID LEUKEMIA AND MULTIPLE MYELOMA USING NATURAL KILLER CELLS IN (57) : Provided herein are methods of treating acute myeloid leukemia (AML) and multiple myeloma (MM) by administering in an effective amount of a cell population comprising natural killer cells, wherein the cell population comprising natural killer cells is ,t: produced by a three- stage method comprising culturing a population of hematopoietic stem or progenitor cells in media comprising 01 stem cell mobilizing factors, e.g., three-stage methods of producing NK cells in media comprising stem cell mobilizing factors starting 1-1 --.... with hematopoietic stem or progenitor cells from cells of the placenta, for example, from placental perfusate (e.g., human placental Ir- perfusate) or other tissues, for example, umbilical cord blood or peripheral blood. Further provided herein are methods of using the 1-1 C NK cells produced by the three-stage methods provided herein to suppress the proliferation of acute myeloid leukemia cells. In certain ei embodiments, the NK cells produced by the three-stage methods described herein are used in combination with IL- 2. C